Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 3/20 | 0.71 |
| ▸ | HSD11B1 | P28845 | 7/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | FFAR2 | O15552 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25460818 | 0.98 | HDAC4 (0.73) | HDAC4HSD11B1HDAC1ALDH1A1FFAR2 | |
| SCHEMBL5639340 | 0.95 | HDAC4 (0.68) | HDAC4HSD11B1HDAC1ALDH1A1FFAR2 | |
| SCHEMBL3553242 | 0.91 | HDAC4 (0.62) | HDAC4HSD11B1HDAC1ALDH1A1FFAR2 | |
| SCHEMBL22027296 | 0.85 | HDAC4 (0.51) | HDAC4HSD11B1HDAC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL25460813 | 0.84 | HDAC4 (0.54) | HDAC4HSD11B1HDAC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL3521822 | 0.83 | HDAC1 (0.55) | HDAC4HSD11B1HDAC1ALDH1A1FFAR2 | |
| SCHEMBL5636847 | 0.83 | HDAC4 (0.71) | HDAC4HSD11B1HDAC1ALDH1A1FFAR2 | |
| SCHEMBL16132869 | 0.83 | HDAC4 (1.00) | HDAC4HSD11B1HDAC1ALDH1A1FFAR2 | |
| SCHEMBL7979818 | 0.83 | HDAC4 (0.72) | HDAC4HSD11B1HDAC1ALDH1A1SMN1; SMN2 | |
| SCHEMBL17285705 | 0.83 | HDAC4 (0.65) | HDAC4HSD11B1HDAC1ALDH1A1FFAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230151074-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | CARMOT THERAPEUTICS, INC. | 2023-05-18 | — | — | US | disclosed |
| US-10562878-B2 | Cycloalkylamines as monoamine reuptake inhibitors | SUNOVION PHARAMCEUTICALS INC. (US) | 2020-02-18 | — | — | US | disclosed |
| US-9868718-B2 | Cycloalkylamines as monoamine reuptake inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2018-01-16 | — | — | US | disclosed |
| EP-1976513-B1 | CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | SUNOVION PHARMACEUTICALS INC (US) | 2016-08-24 | — | — | EP | disclosed |
| US-20150126511-A1 | CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | SUNOVION PHARMACEUTICALS INC. | 2015-05-07 | — | — | US | disclosed |
| US-8877975-B2 | Cycloalkylamines as monoamine reuptake inhibitors | SUNOVION PHARMACEUTICALS INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20100190861-A1 | CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | SUNOVION PHARMACEUTICALS INC. | 2010-07-29 | — | — | US | disclosed |
| EP-1976513-A2 | CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | Sepracor, Inc. (US) | 2008-10-08 | — | — | EP | disclosed |
| US-20070203111-A1 | Cycloalkylamines as monoamine reuptake inhibitors | SEPRACOR INC. (US) | 2007-08-30 | — | — | US | disclosed |
| WO-2007081857-A2 | CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | SEPRACOR INC. (US) | 2007-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126511-A1 | CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | SLC18A2, SLC6A2, SLC18A3 | HDAC4 1582/4885HSD11B1 919/4885HDAC1 2499/4885 |
| US-20070203111-A1 | Cycloalkylamines as monoamine reuptake inhibitors | SLC18A2, SLC6A2, SLC18A3 | HDAC4 1582/4885HSD11B1 919/4885HDAC1 2499/4885 |
| US-20100190861-A1 | CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS | SLC18A2, SLC6A2, SLC18A3 | HDAC4 1582/4885HSD11B1 919/4885HDAC1 2499/4885 |
| US-10562878-B2 | Cycloalkylamines as monoamine reuptake inhibitors | SLC18A2, SLC6A2, SLC18A3 | HDAC4 1582/4885HSD11B1 919/4885HDAC1 2499/4885 |
| US-20230151074-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | GIPR, GLP1R, GCGR | HDAC4 2192/4885HSD11B1 2569/4885HDAC1 1302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.